Proton RT for the Treatment of Pediatric Rhabdomyosarcoma

Status Recruiting

Clinical Trial Summary

The main purpose of this study is to see if using proton beam radiation therapy instead of photon beam radiation therapy can reduce side effects from radiation treatment for rhabdomyosarcoma. Photon beam radiation is the standard type of radiation for treating most rhabdomyosarcoma and many other types of cancer. Photon beam radiation enters the body and passes through healthy tissue, encounters the tumor, then leaves the body through healthy tissue. A beam of proton radiation enters the body and passes through healthy tissue, encounters tumor, but then stops. This means that less healthy tissue is affected by proton beam radiation than by photon beam radiation.

Clinical Trial Description

- A special device is made for each participant to help them hold still during the treatment. This may be in the form of a mask or a custom made foam cradle depending on the area to be treated. - Radiation treatments will be given once per day, 5 days a week for a total of 4 to 6 weeks, depending upon how much total dose the tumor requires. - Participants will be seen once per week by their radiation doctor to monitor health and record any side effects from treatment. - After the radiation treatments are completed, participants will be required to undergo further tests and evaluations for several years following treatment. ;

Study Design

Related Conditions & MeSH terms

Rhabdomyosarcoma

Clinical Trial Details

NCT number	NCT00592592
Study type	Interventional
Source	Massachusetts General Hospital
Contact	Torunn Yock, MD
Phone	617-724-1836
Status	Recruiting
Phase	Phase 2
Start date	October 2004
Completion date	August 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04388839` - Evolutionary Therapy for Rhabdomyosarcoma	Phase 2
Withdrawn	`NCT04906876` - A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas	Phase 2
Completed	`NCT01674101` - Effects of Preoperative Physical Therapy in Patients With Lower Extremity Malignancy	N/A
Completed	`NCT00520936` - A Study of Pemetrexed in Children With Recurrent Cancer	Phase 2
Completed	`NCT03655587` - Impact of an Orthotic Intervention in Children With Peripheral Neuropathy	N/A
Recruiting	`NCT06094101` - Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision)	Phase 1/Phase 2
Recruiting	`NCT04625907` - FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma	Phase 1/Phase 2
Active, not recruiting	`NCT04095221` - A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma	Phase 1/Phase 2
Completed	`NCT01661400` - Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors	Phase 1
Recruiting	`NCT04337177` - Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors	Phase 1
Active, not recruiting	`NCT02945800` - Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma	Phase 2
Not yet recruiting	`NCT06029465` - Analyzing Engagement Trends in Rhabdomyosarcoma Clinical Trials
Terminated	`NCT02536183` - A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors	Phase 1
Completed	`NCT00187174` - Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors	Phase 1
Completed	`NCT01505569` - Auto Transplant for High Risk or Relapsed Solid or CNS Tumors	N/A
Active, not recruiting	`NCT03220035` - Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)	Phase 2
Completed	`NCT05093322` - A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors	Phase 1/Phase 2
Completed	`NCT04956198` - Drug Sensitivity and Mutation Profiling
Recruiting	`NCT04791228` - A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors	Phase 2
Active, not recruiting	`NCT03709680` - Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors	Phase 1/Phase 2